|
Chulkov V.S., Okonenko T.I., Khrutsky A.K., Zhmaylova S.V.
Cost of medicamentous therapy and clinical characteristics of patients with late stage rheumatoid arthritis and arterial hypertension
|
№7 / 2024
|
|
|
№3 (приложение) / 2023
|
|
Kudina E.V. Samkova I.A.
Anti-inflammatory therapy of joint syndrome in an outpatient practitioner
|
№1 / 2023
|
|
Meshkov A.D., Maslyansky A.L., Tkacheva O.N., Mazurov V.I.
Treatment of giant cell arteritis: current possibilities and prospects of steroid-sparing therapy
|
№1 / 2023
|
|
Samigullina R.R., Vasilenko E.A., Mazurov V.I.
Influence of comorbid pathology at the course of spondyloarthritis in patients receiving genetically engineered biological therapy
|
№1 / 2023
|
|
Nasonov E.L.
Pharmacotherapy of immuno-inflammatory rheumatic diseases: new opportunities
|
№6 / 2019
|
|
V.P. Tyurin, S. Ju. Davidjan, N.A. Kirjukhina
The experience of monoclonal antibody to interleukin 17 (secukinumab) use in case of spondyloarthrites in real clinical practice conditions
|
№4 / 2018
|
|
A.M. Lila, E.L. Nasonov, Ju. A. Olyunin, E.A. Galushko
Actual aspects of modern rheumatology
|
№4 / 2018
|
|
Ye.L. Nasonov
Pharmacotherapy of rheumatoid arthritis
|
№4 / 2017
|
Русский
